Seqstant's core product, LiveGene, provides a one-click approach that enables fully automatable pathogen analytics via sequencing, covering the workflow from device start to report. LiveGene is designed to accelerate and simplify the diagnostic sequencing process, delivering faster and more precise diagnoses. The company says earlier and more targeted patient treatment is an expected outcome of the improved diagnostics. Seqstant completed a €1.8 million seed investment round to support its next steps. The funds will be used to further develop LiveGene, strengthen the team, and expand the company's reach in medical diagnostics.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2023